Aegis out positive on Catalyst, CytRx after news

Aegis is out with bullish commentary on both Catalyst Pharmaceuticals (CPRX +5.4%) and CytRx (CYTR +7.6%), both of which are moving higher today on news.

"Time to completion of enrollment of the Firdapse Phase 3 trial has been extended into the first quarter of this year, but we remain confident that the enrollment pace is progressing adequately," analyst Ram Selvaraju says, maintaining a Buy rating and a $6 target on CPRX.

As for CYTR, Selvaraju lifts his target to $9 from $8 after discussing results from additional statistical analyses of a Phase 2b aldoxorubicin study.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs